Healthcare >> Analyst Interviews >> October 1, 2020
Smaller Companies Filling the Void in Neuroscience Drug Development
Vamil Divan, M.D., is a Managing Director and Senior Analyst responsible for coverage of the biopharmaceuticals sector at Mizuho Americas. He joined the equity research department at Mizuho in October 2019. Prior to Mizuho, Dr. Divan was at Credit Suisse, where he spent more than a decade covering the U.S. pharmaceutical sector. Prior to Wall Street, Dr. Divan had worked in the pharmaceutical industry for more than five years at Roche and then Pfizer Inc. He is a board-certified internist and was a practicing physician before he transitioned into the pharmaceutical industry. Dr. Divan holds a medical degree from the University of Buffalo, an MBA from New York University and a B.S. in health care administration and policy from the University of Pennsylvania. Profile
Word count: 4,370
TWST: Could you tell me about your firm?
Dr. Divan: Mizuho Americas is part of Japan-based Mizuho Financial Group, offering corporate and